- Home
- PDSB vs CUE Comparison
PDSB vs CUE Comparison
Compare PDSB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- CUE
- Stock Information
- Founded
- PDSB 2005
- CUE 2014
- Country
- PDSB United States
- CUE United States
- Employees
- PDSB N/A
- CUE N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- CUE Health Care
- Exchange
- PDSB Nasdaq
- CUE Nasdaq
- Market Cap
- PDSB 58.7M
- CUE 60.6M
- IPO Year
- PDSB N/A
- CUE 2018
- Fundamental
- Price
- PDSB $1.34
- CUE $1.01
- Analyst Decision
- PDSB Strong Buy
- CUE Strong Buy
- Analyst Count
- PDSB 3
- CUE 4
- Target Price
- PDSB $14.00
- CUE $4.75
- AVG Volume (30 Days)
- PDSB 1.3M
- CUE 168.5K
- Earning Date
- PDSB 05-14-2025
- CUE 05-08-2025
- Dividend Yield
- PDSB N/A
- CUE N/A
- EPS Growth
- PDSB N/A
- CUE N/A
- EPS
- PDSB N/A
- CUE N/A
- Revenue
- PDSB N/A
- CUE $9,532,000.00
- Revenue This Year
- PDSB $5,518.68
- CUE $73.11
- Revenue Next Year
- PDSB N/A
- CUE $11.02
- P/E Ratio
- PDSB N/A
- CUE N/A
- Revenue Growth
- PDSB N/A
- CUE 149.53
- 52 Week Low
- PDSB $1.13
- CUE $0.45
- 52 Week High
- PDSB $4.92
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- PDSB 50.27
- CUE 39.50
- Support Level
- PDSB $1.30
- CUE $0.92
- Resistance Level
- PDSB $1.41
- CUE $1.03
- Average True Range (ATR)
- PDSB 0.10
- CUE 0.08
- MACD
- PDSB 0.02
- CUE 0.00
- Stochastic Oscillator
- PDSB 60.61
- CUE 39.67
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.